 |
|
|
| |
Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in Caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF)
|
| |
| |
Reported by Jules Levin
AASLD 2014 Boston Nov 7-11
G Papatheodoridis1, G Dalekos2, V Sypsa3, C Yurdaydin4, M Buti5, J Goulis6, H Chi7, S Manolakopoulos8, G Mangia9, N Gatselis2, O Keskin4, S Savvidou6, BE Hansen7, i Vlachogiannakos1, K Galanis2, R idilman4, M Colombo9, R Esteban5, HLA Janssen7,10, P Lampertico9. 1Academic Dept. of Gastroenterology, Laiko Hospital of Athens, Greece; 2Dept. of internal Medicine, Thessalia Univ. Medical School, Greece; 3Dept. of Hygiene & Epidemiology, Athens Univ. Medical School, Greece; 4Dept. of Gastroenterology, Univ. of Ankara Medical School, Ankara, Turkey; 5Hospital General Universitario Valle Hebron and Ciberehd, Barcelona, Spain; 64th Dept. of internal Medicine, Aristotle Univ. of Thessaloniki Medical School, Greece; 7Dept. of Gastroenterology & Hepatology, ErasmusMC, Rotterdam, The Netherlands; 82nd Academic Dept. of internal Medicine, Hippokratio Hospital of Athens, Greece; 91st Division of Gastroenterology, Fondazione iRCCS Cą Granda Ospedale Maggiore Policlinico, Universitą degli Studi di Milano, Milano, italy; 10Liver Clinic, Toronto Western & General Hospital, Univ. Health Network, Toronto, Canada.
|
| |
|
|
|
|
|
